FIELD: immunology, pharmaceutical compositions.
SUBSTANCE: invention relates to application of antibody and/or chemokine construct which bonds to chemokine receptor to produce pharmaceutical composition for elimination of cells, being latently infected with primate immunodeficiency virus. Also are disclosed pharmaceutical compositions for treatment, prevention and/or alleviation of kidney and intestine inflammation, multiple sclerosis, skin diseases, diabetes, or transplant abruption. Antibody construct includes binding site to chemokine 5 receptor and binding site to CD3 receptor; chemokine construct includes RANTES and toxin. Polynucleotides encoding said antibody and/or chemokine constructs, vectors and hosts, containing nuclear acid molecules also are disclosed.
EFFECT: new agents for genetic treatment of immunological disorders.
77 cl, 12 ex, 4 tbl, 23 dwg
